First Tracks Biotherapeutics, Inc. (TRAX)

TRAX Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cost of Revenue	139.61	139.61	152.35	-
Gross Profit	-139.61	-139.61	-152.35	-
Selling, General & Admin	48.43	39.39	28.76	20.87
Research & Development	-7.51	-	-	90.26
Operating Expenses	40.92	39.39	28.76	111.12
Operating Income	-180.54	-179.01	-181.1	-111.12
Interest & Investment Income	11.18	12.94	17.38	12.31
Other Non Operating Income (Expenses)	-0.02	-0.02	0.01	-0
EBT Excluding Unusual Items	-169.38	-166.09	-163.71	-98.81
Pretax Income	-169.38	-166.09	-163.71	-106.15
Net Income	-169.38	-166.09	-163.71	-106.15
Net Income to Common	-169.38	-166.09	-163.71	-106.15
Free Cash Flow	-130.55	-143.01	-126.16	-93.81
EBITDA	-180	-178.45	-180.5	-110.47
D&A For EBITDA	0.54	0.56	0.61	0.65
EBIT	-180.54	-179.01	-181.1	-111.12

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 21, 2026

Data Sources Report a data error